Article

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors

2013-01-01

Abstract excerpt

No abstract is available from the source.

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0b2bfb31-603a-5023-9fee-600727433f31
DOI: 10.1016/j.ypat.2012.10.041

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF InhibitorsDOI 10.1016/j.ypat.2012.10.041Read

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.Semantic proximity Read

New insight into BRAF mutations in cancer.Semantic proximity Read

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.Semantic proximity Read

Mutations of the BRAF gene in human cancerSemantic proximity Read

Clinicopathological relevance of BRAF mutations in human cancerSemantic proximity Read

Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?Semantic proximity Read

Novel inhibitors in the treatment of metastatic melanoma.Semantic proximity Read

Progression of NRAS and BRAF mutations in cutaneous melanoma.Semantic proximity Read

Mutations of the BRAF gene in squamous cell carcinoma of the head and neck.Semantic proximity Read

N-Ras mutation in vemurafenib-associated expanding melanocytic nevus.Semantic proximity Read

Epidermal Growth Factor Receptor P753S Mutation in Cutaneous Squamous Cell Carcinoma Responsive to Cetuximab-Based Therapy.Semantic proximity Read

Vemurafenib-associated keratoses with genetic heterogeneity of RAS.Semantic proximity Read